Conversation

@valhalla @Dangerous_beans Referring to your first paragraph, that doesn’t match what I’ve seen. In the US the FDA provides accelerated approval pathways for orphan indications, for example, in part to reduce development costs and incentivise R&D by (for profit) biotechs who might otherwise ignore them and focus on the “big 3” indications (heart disease, diabetes, and cancer, which are where the biggest revenue opportunities are).

As an aside, it’s interesting to note that states/“taxpayers” also impose costs (with good reason - I fully support that role for regulations) on drug developers. The myth that it’s all one-way subsidy of drug developers falls apart when looked at like that too.